Since early May, a severe outbreak of the Bundibugyo strain of the Ebola virus (a type of filovirus) has spread rapidly through the Democratic Republic of the Congo and neighboring Uganda. With over 1,000 confirmed infections and more than 290 fatalities already recorded across multiple nations, the second largest Ebola outbreak on record crossed a new threshold this week when France confirmed Europe’s first case in a returning humanitarian physician.
The Countermeasure Vulnerability
There are currently no FDA-licensed vaccines or therapeutics available for Bundibugyo. Existing Medical Counter Measures (MCMs) against Ebolavirus exclusively target the Zaire strain, which is more commonly the cause of outbreaks. Treatment for Bundibugyo Ebola Virus (BDBV) only consists of supportive care for Ebola disease symptoms. This outbreak is now the largest caused by the Bundibugyo virus, which has previously caused two outbreaks with death rates of 32% in the Uganda-centered 2007 outbreak and 55% in the Democratic Republic of the Congo-centered outbreak in 2012.
Health officials from the Africa Centres for Disease Control and Prevention estimate containment costs for this outbreak could reach $1.4 billion. In direct alignment with this figure, the White House submitted a request for emergency funding to Congress earlier this week. The $1.4 billion White House request signals an impending mobilization of capital to accelerate the development, testing, and procurement of BDBV-specific countermeasures, as well as provision of humanitarian aid and containment measures. Agencies like the Biomedical Advanced Research and Development Authority (BARDA) are tasked with closing the MCM gap.
Federal Procurement Activity
Since the beginning of the outbreak, federal agencies have been working to jumpstart the pipeline for BDBV defenses. Earlier this month, BARDA utilized the Rapid Response Partnership Vehicle (RRPV) to release a targeted solicitation (RRPV 26-13-BundiVx) accelerating investigational vaccine candidates specifically for BDBV. The BundiVx program represents the immediate U.S. government response to fill the MCM gap, backed by an estimated $75 million in initial funding across one to three anticipated awards.
This BDBV-specific action builds on an existing strategy by the Administration for Strategic Preparedness and Response (ASPR) and BARDA to secure the filovirus countermeasure supply chain. Recent initiatives include efforts to onshore the production of critical viral hemorrhagic fever vaccines. The government is also funding optimization efforts to enhance the production efficiency of monoclonal antibody cocktails for treatment. Further upstream, broad agency initiatives are targeting AI-enabled discovery of small-molecule inhibitors of various diseases, as well as highly adaptable vaccine platforms.
What This Means for Innovators
A significant portion of the proposed $1.4 billion supplemental request will flow through agencies like BARDA, the NIH, and the CDC. These funds will support late-stage clinical trials, manufacturing scale-up, and advanced research into pan-filovirus solutions.
Companies developing rapid-response vaccine platforms, broad-spectrum antivirals against the filoviruses, or rapid field diagnostics need to engage with the federal government immediately. Due to the time-sensitive nature of the outbreak, federal agencies will likely prioritize mature technologies, demonstrated manufacturing capabilities, and teams capable of moving quickly. Navigating rapid-response contract vehicles requires a clear understanding of regulatory pathways and the capacity to meet federal contracting requirements.
EverGlade is a national advisory firm helping innovators navigate the federal funding ecosystem. We support companies across the funding lifecycle, from early-stage strategy through proposal development, negotiations, and post-award execution, ensuring you win the award and deliver the program.
For additional information or to discuss positioning your approach to help contain the BDBV outbreak to federal agencies, schedule a conversation with our team.
